Antibody-drug conjugates combine targeting antibodies with powerful cytotoxic payloads, but clinical performance increasingly depends on linker chemistry, drug-to-antibody ratio, payload properties and how the medicine behaves inside heterogeneous tumors.
Gilead’s Tubulis deal strengthens its ADC pipeline, but oncology execution, safety and clinical proof now decide the upside.
EMA begins review of ENHERTU plus pertuzumab for first-line HER2-positive metastatic breast cancer. Find out what this means for frontline therapy options.
Rakuten Medical taps LOTTE Biologics for global supply of its Alluminox cancer platform. Find out what this deal means for photoimmunotherapy’s future.
Celltrion is going all-in on oncology biologics with ADCs, msAbs, and U.S. biomanufacturing scale-up. Find out what this shift means for global competition.